---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-157864"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:10:41.933396+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon announces proposed public offering and concurrent private placement to fund INPEFA launch

## Summary
- FDA approved INPEFA (sotagliflozin) on May 26, 2023 for heart failure and type 2 diabetes with CKD.
- Company expects commercial availability by end of June; sales team booked over 5,000 appointments.
- Proposed underwritten public offering of common stock; concurrent private placement to Invus affiliate.
- Net proceeds to fund commercial launch of INPEFA, R&D, and working capital.
- Bookrunners: Citigroup, Jefferies, Piper Sandler; 30-day over-allotment option to underwriters.

## SEC filing metadata
- accession: 0001193125-23-157864
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000119312523157864/0001193125-23-157864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000119312523157864/d507509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-157864
- JSON: https://secwatch.observer/filing/0001193125-23-157864.json
- Plain text: https://secwatch.observer/filing/0001193125-23-157864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.